

KCPP Rheumatology Clinical Trials: Providers

DX	Protocol	Medication	Purpose	Eligibility	Study Design	Enrollment
RA	SetPoint SPM-020	VNS Stimulator Implant	<ul style="list-style-type: none"> Are Vagal Nerve Stimulators effective in treating RA disease activity? 	<ul style="list-style-type: none"> 22-75 years old Stable use of csDMARD Failed at least 1 bDMARD or tsDMARD 4 tender / 4 swollen joints No tobacco use No uncontrolled fibromyalgia or cardiovascular disease 	<ul style="list-style-type: none"> Sham (inactive) 1:1 first 12 weeks then everyone on active device 4 year study Implanted by local surgeon after preop clearance and evaluation 	Closed
RA	Abbvie M23-700	Rinvoq vs Humira	<ul style="list-style-type: none"> Cycle or Switch? If subject has failed 1 TNFi (Humira), then should they be Cycled another TNFi or Switched to a different class such as Jaki-Rinvoq? 	<ul style="list-style-type: none"> Dx RA > 3 mon On background MTX Failed 1 TNF (except humira) 6 tender & 6 swollen joints hsCRP >3mg mg/L No Hx of JAK or Humira use No active fibromyalgia 	<ul style="list-style-type: none"> 48 week treatment Visits q 3 month after week 12 All patients get oral + injection – one is inactive to maintain blind After 12 weeks dose changes to background DMARDs may occur 	Active
SLE	Abbvie M23-699	Rinvoq	<ul style="list-style-type: none"> To evaluate efficacy of Rinvoq for moderate to severe active SLE. 	<ul style="list-style-type: none"> 18-63 years old Seropositive SLE > 6 months SLEDAI >=6 On background treatment of antimalarial, corticosteroid, or conventional DMARD 	<ul style="list-style-type: none"> 2 year trial, Placebo control 1:1 for 52 weeks followed by 52 week Rinvoq extension Can adjust background tx if needed 	Active
Sjogrens	Amgen	Dazodalibep	<ul style="list-style-type: none"> To evaluate the efficacy of dazodalibep on systemic 	<ul style="list-style-type: none"> moderate-to-severe systemic disease activity defined by ESSDAI score ≥ 5 	<ul style="list-style-type: none"> Randomized, double-blind, placebo-controlled, parallel-arm stud 	Feb 2024

			manifestations of SS in participants with moderate-to-severe systemic disease activity.	<ul style="list-style-type: none">• Seropositive Sjogrens• Ie: Sicca symptoms + another manifestation (arthritis)		
--	--	--	---	--	--	--

KCPP in collaboration with Arizona Arthritis & Rheumatology Research

Micah Judd

Clinical Research Coordinator

Mjudd@mykcpp.com

Micah.Judd@azarthritis.com

Call 816-268-7512

Rebecca Martinez

Clinical Research Operations Manager

Rebecca.Martinez@azarthritis.com

Call or text 928-699-6947